| Row | Compact knowledge-base content | Evidence |
|---|---|---|
| Disease identifiers / names | **Primary disease concept:** UCHL1-related neurodegeneration with optic atrophy and spastic paraplegia; **related indexed entities:** **MONDO:0014209** early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome; **MONDO:0859363** spastic paraplegia 79A, autosomal dominant, with ataxia; **Orphanet:352654** Early-onset progressive neurodegeneration - blindness - ataxia - spasticity; also placed within **spastic paraplegia / SPG79** disease space. Information is derived mainly from aggregated disease resources plus very small published case series/families. | (pqac-00000014, pqac-00000007, pqac-00000001) |
| Gene / protein | **Gene:** UCHL1; **Ensembl:** **ENSG00000154277**; **Protein:** ubiquitin C-terminal hydrolase L1 (UCH-L1), a neuron-enriched deubiquitinase/ubiquitin-processing enzyme that is highly abundant in brain and required for axonal integrity maintenance. Suggested ontology: GO **deubiquitination / ubiquitin-dependent protein catabolic process**. | (pqac-00000014, pqac-00000002, pqac-00000005) |
| Inheritance / allelic spectrum | **Established recessive disease:** biallelic loss-of-function/function-impairing UCHL1 variants causing early-onset progressive neurodegeneration with blindness/optic atrophy, ataxia, and spasticity; includes autosomal recessive SPG79 reports. **Expanded dominant spectrum:** 2023 report established **heterozygous loss-of-function variants** causing a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy, consistent with dominant/haploinsufficient disease concept indexed as MONDO:0859363. | (pqac-00000001, pqac-00000007, pqac-00000014) |
| Core phenotypes with suggested HPO terms | **Motor system:** spastic paraplegia/spasticity (**suggested HPO:** Spastic paraplegia, Spasticity, Hyperreflexia, Extensor plantar response); **cerebellar:** ataxia/gait ataxia (**suggested HPO:** Cerebellar ataxia, Gait ataxia); **optic/visual:** optic atrophy, progressive visual loss/blindness (**suggested HPO:** Optic atrophy, Decreased visual acuity, Blindness); **peripheral nerve:** sensory-motor or motor axonal neuropathy (**suggested HPO:** Peripheral neuropathy, Axonal neuropathy); **other reported in expanded spectrum:** upper motor neuron degeneration, neuromuscular junction denervation. Frequencies are not well defined because published human cohorts are extremely small. | (pqac-00000001, pqac-00000007, pqac-00000016, pqac-00000014) |
| Key pathogenic variants / reports | **p.Glu7Ala (E7A):** human missense variant with severely impaired ubiquitin hydrolysis; associated with early-onset neurodegeneration, blindness around childhood, and progressive ataxia/spasticity. **Novel splice-site variant in AR SPG79:** reported in an Indian family with autosomal recessive spastic paraplegia-79. **Heterozygous loss-of-function variants (2023 spectrum paper):** multiple LoF alleles causing dominant disorder with spasticity, ataxia, neuropathy, optic atrophy. Variant-level ACMG assertions and population frequencies should be checked in ClinVar/gnomAD per allele; not fully extractable from current evidence set. | (pqac-00000007, pqac-00000001, pqac-00000014) |
| Mechanism with suggested GO terms | **Upstream defect:** impaired UCHL1 function disrupts ubiquitin recycling and neuronal proteostasis, reducing free monoubiquitin (mouse data ~30% reduction in UCHL1-deficient strains). **Cellular consequences:** accumulation of polyubiquitinated proteins, proteasomal stress/impairment, compensatory autophagy changes, increased ER stress, altered mTOR balance, synaptic vesicle/NMJ degeneration, axonal transport failure, and length-dependent axon degeneration. **Suggested GO terms:** ubiquitin-dependent protein catabolic process; protein deubiquitination; proteasome-mediated ubiquitin-dependent protein catabolic process; response to endoplasmic reticulum stress; regulation of TOR signaling; axon development/maintenance; synapse organization; neuromuscular junction development; autophagy. | (pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000008, pqac-00000009) |
| Anatomy / cell types with suggested UBERON / CL terms | **Primary systems:** central and peripheral nervous systems. **Anatomical sites:** optic nerve/retinal ganglion cell pathway (**suggested UBERON:** optic nerve, retina), corticospinal tract / motor cortex / spinal cord, peripheral axons, neuromuscular junction. **Cell types:** corticospinal motor neurons / upper motor neurons, spinal motor neurons, retinal ganglion cells, peripheral neurons/axons, dopaminergic neurons in fly PD models. **Suggested CL terms:** motor neuron, upper motor neuron, retinal ganglion cell, neuron, dopaminergic neuron. **Subcellular compartments:** synapse/presynaptic terminal, endoplasmic reticulum, lysosome/autophagy pathway, ubiquitin-proteasome system components. | (pqac-00000016, pqac-00000018, pqac-00000015, pqac-00000021) |
| Diagnostics | **Current practical diagnosis:** genomic testing in patients with complex HSP / optic atrophy / ataxia / neuropathy phenotype, typically via exome/genome or curated neurogenetic panels; confirmatory single-gene analysis of **UCHL1** where phenotype fits. Supportive workup may include neuro-ophthalmic examination, electrophysiology for neuropathy, and MRI/neurologic exam as indicated, but no disease-specific biomarker or standardized diagnostic criteria were found. Differential diagnosis includes other complicated HSP and optic atrophy disorders (e.g., mitochondrial/AFG3L2/SPG7/MFN2-related disorders). | (pqac-00000011, pqac-00000012, pqac-00000001) |
| Treatment status | **No disease-modifying therapy established for UCHL1-related disease.** **No relevant disease-specific clinical trial identified** in repeated registry searches. Current care is supportive and extrapolated from HSP practice: oral baclofen or tizanidine for spasticity, intrathecal baclofen in severe cases, botulinum toxin, physiotherapy/orthotics, management of bladder urgency (e.g., oxybutynin), rehabilitation, and genetic counseling. UCHL1-targeted pharmacology exists only as experimental tool biology; not a clinical therapy for this disease. | (pqac-00000010, pqac-00000014) |
| Model organisms / experimental systems | **gad mouse:** spontaneous exon 7-8 deletion; sensory ataxia then motor ataxia, hindlimb paralysis, axonal spheroids, death by ~6 months. **nm3419 mouse:** spontaneous intragenic deletion; progressive corticospinal motor neuron loss, dendrite/spine pathology, ER stress, motor impairment, NMJ denervation. **UCHL1 knockout mouse:** progressive paralysis, presynaptic terminal degeneration, loss of synaptic vesicles, premature death. **C152A knock-in:** models oxidative modification biology and partial neuroprotection after injury rather than inherited SPG79 phenotype. **Drosophila dUCH knockdown:** dopaminergic neurodegeneration, dopamine deficiency, locomotor dysfunction; useful for oxidative-stress and screening studies but does not specifically model optic atrophy/spastic paraplegia syndrome. | (pqac-00000016, pqac-00000017, pqac-00000018, pqac-00000019, pqac-00000020) |
| Major evidence gaps | Disease is **ultra-rare** with very limited human numbers; no robust prevalence/incidence, penetrance, carrier frequency, sex ratio, survival statistics, validated natural-history staging, or genotype-phenotype frequency estimates. No disease-specific fluid biomarker, no validated omics signature, no single-cell/spatial transcriptomic data, no established modifier genes, no proven environmental/protective factors, no prevention strategy beyond genetic counseling/cascade testing, and no approved targeted therapy or interventional trial. Exact ontology IDs for several phenotypes/cell types should be finalized during curation. | (pqac-00000014, pqac-00000001, pqac-00000010) |


*Table: This table condenses the key identifiers, genetics, phenotypes, mechanisms, diagnostics, treatments, models, and evidence gaps for UCHL1-related neurodegeneration. It is designed for direct reuse in a disease knowledge base while clearly separating established facts from current unknowns.*